Navigation Links
ISTA Pharmaceuticals Engages Cowen as Financial Advisor
Date:4/1/2008

IRVINE, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it has engaged Cowen and Company as its financial advisor. For more than a year, ISTA has initiated discussions with other companies and financial sponsors regarding new product opportunities and potential mergers and acquisitions that would allow it to grow the scale of ISTA's business. In addition, ISTA has been approached from to time regarding business combination opportunities. Cowen will assist the Company in evaluating these and other opportunities.

In addition, ISTA reconfirmed certain of its guidance issued during its 2007 fourth quarter and year-end earnings announcement. As previously stated, the Company expects net revenue for 2008 will be approximately $75 to $82 million, and the gross margin for 2008 will be approximately 70% to 73%, subject to quarterly fluctuations based on revenue mix. Finally, ISTA believes it is on track to report results of the Phase III and ocular safety studies of Bepreve(TM) (bepotastine ophthalmic solution) during the second quarter of 2008.

ABOUT ISTA PHARMACEUTICALS

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to anticipated 2008 financial results, and to bringing a new product to market every 12 to 18 months, and becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty of predicting the timing or outcome of product development efforts and the FDA or other regulatory agency approval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and or other governmental regulations applicable to ISTA's facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2007.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
2. Barr Pharmaceuticals, Inc. Executive Bios
3. Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
4. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
5. MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
6. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
7. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
8. Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
9. Alseres Pharmaceuticals, Inc. Raises $5 Million
10. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
11. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... ... gynecological care and gynecological services for women of all ages. The ... a wide variety of reproductive services from routine health screenings to diagnosing and ...
(Date:1/23/2017)... ... ... “Crossing the Bar”: a moving and eloquent drama depicting the events ... is the creation of published author, Charlotte Hotte, a North Carolina native, a mother ... of the book to her sister, Denise, wishes to acknowledge her savior, Jesus Christ, ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: an entrancing story about ... “Life Under Blankets” is the creation of published author, Kimberly Mitchell, who earned her ... She went on to pursue a master’s degree in education in the field of ...
(Date:1/23/2017)... ... ... Valentine’s Day is a time when many people celebrate romance and love by giving cards, ... for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day ... $200 and get $50 free. , “A lot of people just buy the more ...
(Date:1/22/2017)... (PRWEB) , ... January 22, 2017 , ... Zifam Pinnacle, ... across the world, recently met with big-name retail buyers at the January ECRM Trade ... of efficacy and uses the utmost safety standards in all of its creations to ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Stock-Callers.com today presents the following Generic ... CPRX ), Sophiris Bio Inc. (NASDAQ: SPHS ), ... Therapeutics Inc. (NASDAQ: AGRX ). These companies are ... late trade on Friday, January 20 th , 2017, with ... of health care companies in the S&P 500 also were ...
(Date:1/23/2017)... Januar 2017  ResMed (NYSE: RMD ), ... Medical ( Winter Haven, Florida ) gaben ... die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ResMed ... leisten, um das in Florida ...
(Date:1/22/2017)... DAVOS, Switzerland and ABU DHABI , ... leaders from the US ... , Hospital of the Future , at ... in the hospital of the future will be driven by big data and ... better," according to the panel of experts that discussed the ,Hospital of the ...
Breaking Medicine Technology: